Alnylam Pharmaceuticals Executive and Leadership Team

Yvonne Greenstreet, the Chief Executive Officer at Alnylam Pharmaceuticals, directs the company's overall strategy and operational execution. Greenstreet guides the advancement of novel RNAi therapeutics from discovery through commercialization, focusing on rare genetic and common diseases. Overseeing global operations, the Chief Executive Officer ensures alignment with corporate objectives for patient impact and scientific leadership. This leadership role involves expanding market reach for key products like ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. By driving innovation in RNA interference technology, Yvonne Greenstreet directly impacts the company's growth and its mission to transform patient lives. Ultimately, Greenstreet secures long-term financial stability and market leadership in the biopharmaceutical sector.

Vardhanapu Raju, the Chief Financial Officer at Alnylam Pharmaceuticals, manages the company's financial operations and strategic fiscal planning. Raju oversees all aspects of financial reporting, capital allocation, and investor relations, ensuring robust financial health and sustainable growth. Overseeing the finance department, the Chief Financial Officer guides investment decisions in research, development, and commercial expansion. This leadership role involves managing budgets for a diverse portfolio of RNAi therapeutics targeting rare and common diseases. By optimizing financial resources and securing funding, Vardhanapu Raju directly supports the company's ambitious pipeline and global market expansion. Ultimately, Raju ensures financial discipline and strategic resource deployment to advance Alnylam's mission.

Martin Schmieg, the Senior Vice President & Chief Financial Officer at Alnylam Pharmaceuticals, oversees the company's financial strategy and fiscal management. Schmieg directs financial planning, analysis, and reporting, ensuring the company's financial integrity and supporting its growth objectives in the biopharmaceutical sector. Overseeing the financial operations, the Senior Vice President & Chief Financial Officer manages capital allocation and investment strategies for the development of novel RNAi therapeutics. This leadership role involves close collaboration with executive leadership and the board to guide financial decision-making. By ensuring robust financial controls and strategic resource deployment, Martin Schmieg directly contributes to Alnylam's ability to fund its extensive research and development pipeline. Ultimately, Schmieg safeguards the company's financial health and supports its mission to deliver transformative medicines.

Vasant Jadhav, the Chief Technology Officer at Alnylam Pharmaceuticals, architects the company's technological infrastructure and innovation pipeline. Jadhav spearheads the development and implementation of cutting-edge RNAi technologies, ensuring the company remains at the forefront of biopharmaceutical innovation. Overseeing research and development platforms, the Chief Technology Officer drives the scientific exploration of new therapeutic targets and delivery mechanisms. This leadership role involves fostering collaboration with strategic partners like Regeneron and Roche to accelerate drug discovery. By optimizing computational biology and data analytics, Vasant Jadhav directly supports the efficient progression of pipeline assets. Ultimately, Jadhav ensures the technological foundation supports Alnylam's mission to deliver life-changing medicines globally.

Shweta Randeria, the Chief Marketing Officer at Alnylam Pharmaceuticals, shapes the global commercial strategy for the company's innovative therapeutics. Randeria leads the market development and brand positioning for RNAi-based medicines, ensuring broad patient access and physician adoption. Overseeing all marketing functions, the Chief Marketing Officer drives awareness and engagement for products treating conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria. This leadership role involves translating complex scientific advancements into compelling value propositions for diverse stakeholders. By analyzing market trends and patient needs, Shweta Randeria directly contributes to revenue growth and market penetration. Ultimately, Randeria ensures Alnylam's therapeutic innovations reach the patients who need them most across key global markets.

Matthew Dowling, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, supports the strategic initiatives and operational efficiency of the marketing leadership team. Dowling assists in coordinating cross-functional marketing projects and ensuring alignment with the company's commercial objectives for its RNAi therapeutics. Overseeing project management within the marketing division, the Manager, Chief Marketing Officer Management facilitates the execution of global marketing campaigns and market access strategies. This role involves analyzing market data and supporting the development of go-to-market plans for innovative treatments. By streamlining marketing operations and providing critical support, Matthew Dowling directly contributes to the effective promotion of Alnylam's product portfolio. Ultimately, Dowling enhances the marketing team's capacity to reach patients and healthcare providers worldwide.

Danielle Dougherty, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, plays a key role in executing the company's global marketing strategies for its RNAi-based medicines. Dougherty supports the Chief Marketing Officer in managing product launches and ongoing commercial activities, ensuring seamless coordination across various business units. Overseeing specific marketing projects, the Manager, Chief Marketing Officer Management focuses on enhancing brand visibility and market penetration for treatments addressing rare genetic diseases. This leadership position involves collaborating with internal teams and external agencies to optimize marketing communications. By driving project execution and performance tracking, Danielle Dougherty directly contributes to the successful commercialization of Alnylam's therapeutic pipeline. Ultimately, Dougherty ensures marketing initiatives effectively communicate the value of Alnylam's innovations to global audiences.

Elizabeth Bailey, the Senior Executive Assistant To Chief Human Resources Officer at Alnylam Pharmaceuticals, provides critical administrative and operational support to the human resources leadership. Bailey manages complex scheduling, coordinates executive communications, and facilitates the smooth functioning of the HR department, ensuring efficient talent management and employee engagement initiatives. Overseeing executive support functions, the Senior Executive Assistant To Chief Human Resources Officer plays a vital role in maintaining organizational effectiveness. This position involves handling sensitive information and supporting strategic HR planning for a growing biopharmaceutical company. By ensuring seamless administrative operations and facilitating key communications, Elizabeth Bailey directly contributes to the effective execution of Alnylam's human capital strategies. Ultimately, Bailey enables the Chief Human Resources Officer to focus on driving talent development and fostering a positive corporate culture.

Melissa McLaughlin, the Chief Human Resources Officer at Alnylam Pharmaceuticals, leads the company's global human resources strategy and operations. McLaughlin is responsible for talent acquisition, development, compensation, and fostering a high-performance culture to support the company's mission of advancing RNAi therapeutics. Overseeing all HR functions, the Chief Human Resources Officer ensures alignment with business objectives and promotes employee well-being and engagement across the organization. This leadership role involves developing and implementing policies that attract, retain, and motivate a diverse and skilled workforce. By championing organizational development and employee experience initiatives, Melissa McLaughlin directly contributes to Alnylam's success in bringing innovative medicines to patients. Ultimately, McLaughlin builds and sustains a robust organizational foundation essential for scientific and commercial achievements.

Bryan Supran, the Chief Legal Officer at Alnylam Pharmaceuticals, directs the company's legal affairs and ensures compliance with all regulatory requirements. Supran oversees intellectual property strategy, corporate governance, and manages all legal aspects related to drug development, partnerships, and commercialization of RNAi therapeutics. Overseeing the legal department, the Chief Legal Officer provides critical counsel on complex matters, safeguarding the company's interests and assets. This leadership role involves navigating the intricate legal landscape of the biopharmaceutical industry, including patent law and regulatory compliance. By providing strategic legal guidance and risk management, Bryan Supran directly supports Alnylam's innovation and global expansion efforts. Ultimately, Supran ensures the company operates with the highest ethical standards and legal integrity.